Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s shares opened today at $106.81. According to ...

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

(Reuters) - Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com (NASDAQ: AMZN) launched a rival service ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy ...

Top-line results from the study are expected in the first half of 2025. Novo Nordisk NVO acquired Prothena’s clinical-stage antibody, Coramitug (formerly PRX004), a potential first-in-class amyloid ...